Division of Discovery Science and Technology (Bioengineering)

Share:

EmailFacebookLinkedInXWhatsAppShare
Through device engineering and biological engineering, this division supports the development of broadly applicable biomedical technologies (without preference for any disease or application) that directly interface with, monitor, and regulate biological processes and functions of human physiology to enable new paradigms of human health. This division also supports research to advance the design and deployment of future technology-driven interventions.

Device Engineering Programs

Biological and Materials Engineering Programs

Collaborations

An important aspect of the Institute’s mission is encouraging collaborations among the institutes and centers at NIH, other federal agencies, and the private sector.

  • Interagency Modeling and Analysis Group (IMAG) – IMAG brings together program officers across multiple federal agencies to communicate, disseminate, and plan collaborative activities and joint initiatives related to computational modeling and analysis of biomedical, biological, and behavioral systems. IMAG coordinates the Multi-scale Modeling (MSM) Consortium, see IMAG wiki. Contact: Grace Peng
     
  • Synthetic Biology Consortium (SBC) - The SBC is a trans-NIH effort to foster collaborations among researchers and share synthetic biology technologies to address unmet needs in biology and medicine. Contact: Jermont Chen
     
  • Biomaterials Network - The Biomaterials Network consists of a set of connected resources that enable novel and refined technologies to progress through discovery and development to commercialization and clinical use. Contact: Luisa Russell

 

Related News

  • Science Highlights ·

    Typical diagnosis of upper urinary tract cancers requires removal of suspicious tissue with forceps, a technically challenging procedure that only samples one region of the organ. NIBIB-funded researchers are developing preclinical microgrippers that could be deployed throughout the upper urinary tract, which could potentially grab tiny pieces of tissue at hundreds of different areas and someday facilitate early detection of disease.

  • NIBIB in the News ·

    A team of engineers at the University of Houston has published a study in the journal Nature on how international air travel has influenced the spread of COVID-19 around the world. By using a newly developed AI tool, the team identified hotspots of infection linked to air traffic, pinpointing key areas that significantly contribute to disease transmission. Source: University of Houston Newsroom

  • NIBIB in the News ·

    The University of Chicago Pritzker School of Molecular Engineering (PME) has solved a challenge that has long stymied researchers, reimagining the process of creating hydrogels to build a powerful semiconductor in hydrogel form that can be used to create better brain-machine interfaces, biosensors, and pacemakers. Source: UChicago Pritzker School of Molecular Engineering News.

  • Science Highlights ·

    NIBIB-funded researchers are working to bring in vivo gene editing to the fore. Through rational engineering of lipid nanoparticles, this collaborative team developed a way to effectively target specific organs in the body to precisely deliver therapeutic cargo, including gene-editing molecules. Their research demonstrated that a one-time treatment with their nanoparticles resulted in durable gene editing in mouse lungs for nearly two years. Further, their technique showed promise in correcting a mutation present in a currently untreatable form of cystic fibrosis in several models of the disease.

  • NIBIB in the News ·

    As strains of pathogens resistant to frontline antibiotics become more common worldwide, clinicians are more often turning to combination treatments that degrade this resistance as a first treatment option.

    Researchers from Duke University have discovered the mechanism behind why some antibiotic-resistant pathogens haven't adapted to the combination treatments—the bacteria’s level of “selfishness.” The insight provides guidance to clinicians on how to best tailor these combination treatments to different pathogens, minimize the selection for resistance and formulate new antibiotic resistance inhibitors.  Source: Duke University Pratt School of Engineering